Melissa Rock, NP
Family · Corpus Christi, TXNPI 1588011639
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$842
- Lilly USA, LLC$602
- AbbVie$423
- Pfizer$389
- Takeda Pharmaceuticals U.S.A., Inc.$252
- Sumitomo Pharma America, Inc.$236
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,168100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $842 |
| Lilly USA, LLC | 37 | $602 |
| AbbVie | 22 | $423 |
| Pfizer | 19 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $252 |
| Sumitomo Pharma America, Inc. | 10 | $236 |
| Bayer | 9 | $234 |
| Merck | 7 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $120 |
| GSK | 5 | $118 |
| Amgen | 4 | $85 |
| Shield Therapeutics Inc | 5 | $74 |
| Phathom Pharmaceuticals, Inc. | 4 | $69 |
| AstraZeneca | 3 | $59 |
| Boehringer Ingelheim | 3 | $59 |
| Ardelyx, Inc. | 3 | $57 |
| Corcept Therapeutics | 3 | $55 |
| Exact Sciences | 3 | $53 |
| Eisai Inc. | 2 | $52 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $35 |
| Tonix Medicines, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Enterra Medical, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Organon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,173 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 17 | $24,093 |
| MounjaroTirzepatide | 18 | $23,347 |
| JardianceEmpagliflozin | 12 | $15,856 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,058 |
| Gabapentin | 73 | $1,629 |
| Atorvastatin Calcium | 114 | $1,086 |
| Omeprazole | 34 | $796 |
| Duloxetine Hcl | 21 | $763 |
| Metformin Hcl | 62 | $701 |
| Levothyroxine Sodium | 79 | $688 |
| Famotidine | 29 | $687 |
| Lisinopril | 61 | $527 |
| Metoprolol Succinate | 31 | $470 |
| Amlodipine Besylate | 62 | $457 |
| Pravastatin Sodium | 48 | $443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $842 | $24,09317 claims |
| Lilly USA, LLCMounjaro | $602 | $23,34718 claims |
| Boehringer IngelheimJardiance | $59 | $15,85612 claims |
| AstraZenecaSymbicort | $59 | $3,05811 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $20 | $68879 claims |
| PfizerPaxlovid | $389 | $015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Corpus Christi
- Stephanie RodriguezCorpus Christi$159K
- Katie MontgomeryCorpus Christi$29K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.